Prostate Cancer Program The Prostate Cancer Program (PCP) aims to advance and exploit scientific knowledge that will reduce the morbidity and mortality attributed to prostate cancer and lead to improvements in patients' quality of life. The PCP has three primary areas of focus where cooperative efforts (allocation of resources; faculty recruitments; scientific collaborations) are coordinated to make substantive advancements: 1) understanding the heritable and environmental risk factors contributing to prostate cancer development, progression, and lethality; 2) targeting mechanisms contributing to castration-resistant prostate cancer progression; and, 3) distinguishing lethal from indolent prostate cancer through discovery and validation of prognostic biomarkers and a treatment plan that affords longitudinal assessments and attenuation of risk. The P30 CCSG supports this research program by providing: key shared resources, particularly Comparative Medicine, Specimen Processing, Genomics, and Research Pathology; administrative and logistical support for PCP meetings, pilot funding for new clinical and translational research projects, and recruitment grants for new faculty. The Prostate Cancer Program currently has 32 members from 3 schools/divisions, 10 departments and 2 institutions. Eight members have primary appointments at FHCRC and 24 at UW. 29 Members (90%) have peer-reviewed funding, are PI on a clinical trial, or are newly recruited and supported by institutional funds. The current research support of PCP members comprises $6.5M in peer-reviewed funding of which $4.4M (68%) is from the NCI (direct dollars.) Due to the efforts in promoting inter-disciplinary studies, a substantial component of the research funding is in the form of P50, P01, and other collaborative grants. Of the 417 newly treated prostate cancer patients, 66 (16%) were enrolled onto therapeutic clinical trials in 2013. The program published a total of 458 papers in the previous grant period. 24% were inter-institutional, 32% were intra-programmatic and 20% were inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617728
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications